Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Delayed emergence of methamphetamine's enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence.

Vaupel DB, Schindler CW, Chefer S, Belcher AM, Ahmet I, Scheidweiler KB, Huestis MA, Stein EA.

Drug Alcohol Depend. 2016 Feb 1;159:181-9. doi: 10.1016/j.drugalcdep.2015.12.008. Epub 2015 Dec 24.

2.

A novel method to induce nicotine dependence by intermittent drug delivery using osmotic minipumps.

Brynildsen JK, Najar J, Hsu LM, Vaupel DB, Lu H, Ross TJ, Yang Y, Stein EA.

Pharmacol Biochem Behav. 2016 Mar;142:79-84. doi: 10.1016/j.pbb.2015.12.010. Epub 2016 Jan 2.

3.

Abstinence from cocaine and sucrose self-administration reveals altered mesocorticolimbic circuit connectivity by resting state MRI.

Lu H, Zou Q, Chefer S, Ross TJ, Vaupel DB, Guillem K, Rea WP, Yang Y, Peoples LL, Stein EA.

Brain Connect. 2014 Sep;4(7):499-510. doi: 10.1089/brain.2014.0264.

4.

Withdrawal from long-term methamphetamine self-administration 'normalizes' neurometabolites in rhesus monkeys: a (1) H MR spectroscopy study.

Yang S, Belcher AM, Chefer S, Vaupel DB, Schindler CW, Stein EA, Yang Y.

Addict Biol. 2015 Jan;20(1):69-79. doi: 10.1111/adb.12078. Epub 2013 Aug 4.

5.

fMRI response in the medial prefrontal cortex predicts cocaine but not sucrose self-administration history.

Lu H, Chefer S, Kurup PK, Guillem K, Vaupel DB, Ross TJ, Moore A, Yang Y, Peoples LL, Stein EA.

Neuroimage. 2012 Sep;62(3):1857-66. doi: 10.1016/j.neuroimage.2012.05.076. Epub 2012 Jun 1.

6.

Acute nicotine-induced tachyphylaxis is differentially manifest in the limbic system.

Zuo Y, Lu H, Vaupel DB, Zhang Y, Chefer SI, Rea WR, Moore AV, Yang Y, Stein EA.

Neuropsychopharmacology. 2011 Nov;36(12):2498-512. doi: 10.1038/npp.2011.139. Epub 2011 Jul 27.

7.

Temporary disruption of the rat blood-brain barrier with a monoclonal antibody: a novel method for dynamic manganese-enhanced MRI.

Lu H, Demny S, Zuo Y, Rea W, Wang L, Chefer SI, Vaupel DB, Yang Y, Stein EA.

Neuroimage. 2010 Mar;50(1):7-14. doi: 10.1016/j.neuroimage.2009.12.053. Epub 2009 Dec 21.

8.

When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor.

Su TP, Hayashi T, Vaupel DB.

Sci Signal. 2009 Mar 10;2(61):pe12. doi: 10.1126/scisignal.261pe12. Review.

9.

Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.

Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA.

J Nucl Med. 2008 Oct;49(10):1628-35. doi: 10.2967/jnumed.108.050716. Epub 2008 Sep 15.

10.

NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation.

Chefer SI, Pavlova OA, Zhang Y, Vaupel DB, Kimes AS, Horti AG, Stein E, Mukhin AG.

J Neurochem. 2008 Jan;104(2):306-15. Epub 2007 Nov 6.

11.

Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380.

Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Vaupel DB, Stein EA, Mukhin AG.

Neuroimage. 2008 Jan 15;39(2):717-27. Epub 2007 Sep 19.

12.

Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380.

Vaupel DB, Stein EA, Mukhin AG.

Neuroimage. 2007 Feb 15;34(4):1352-62. Epub 2006 Dec 20.

13.
14.
15.

Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography.

Vaupel DB, Tella SR, Huso DL, Wagner VO 3rd, Mukhin AG, Chefer SI, Horti AG, London ED, Koren AO, Kimes AS.

J Pharmacol Exp Ther. 2005 Jan;312(1):355-65. Epub 2004 Aug 26.

PMID:
15331657
16.

Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET.

Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A, Seneca N, Tipre D, DeNucci CC, Iida H, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP, Baldwin RM, Innis RB.

Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1620-9. Epub 2003 Oct 2.

PMID:
14523584
17.

2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans.

Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, Friello P, Koren AO, Kurian V, Matochik JA, Pavlova O, Vaupel DB, Mukhin AG.

FASEB J. 2003 Jul;17(10):1331-3. Epub 2003 May 20.

PMID:
12759330
18.

Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects.

Fujita M, Seibyl JP, Vaupel DB, Tamagnan G, Early M, Zoghbi SS, Baldwin RM, Horti AG, KoreN AO, Mukhin AG, Khan S, Bozkurt A, Kimes AS, London ED, Innis RB.

Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):183-90.

PMID:
11926380
19.

5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.

Mukhin AG, G√ľndisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, Chambers J, Vaupel DB, King SL, Picciotto MR, Innis RB, London ED.

Mol Pharmacol. 2000 Mar;57(3):642-9.

PMID:
10692507
20.

Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors.

Horti AG, Koren AO, Lee KS, Mukhin AG, Vaupel DB, Kimes AS, Stratton M, London ED.

Nucl Med Biol. 1999 Feb;26(2):175-82.

PMID:
10100216
21.

In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand.

Vaupel DB, Mukhin AG, Kimes AS, Horti AG, Koren AO, London ED.

Neuroreport. 1998 Jul 13;9(10):2311-7.

PMID:
9694220
22.

Effect of cocaine-related environmental stimuli on the spontaneous electroencephalogram in polydrug abusers.

Liu X, Vaupel DB, Grant S, London ED.

Neuropsychopharmacology. 1998 Jul;19(1):10-7.

24.
25.

Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal.

Vaupel DB, Kimes AS, London ED.

Neuropsychopharmacology. 1995 Dec;13(4):315-22. Review.

26.

Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal.

Vaupel DB, Kimes AS, London ED.

Psychopharmacology (Berl). 1995 Apr;118(4):361-8.

PMID:
7568621
27.

Inhibitors of nitric oxide synthase and the opioid withdrawal syndrome.

London ED, Kimes AS, Vaupel DB.

NIDA Res Monogr. 1995;147:170-81. Review.

PMID:
8742786
28.

Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans.

Vaupel DB, Lange WR, London ED.

J Pharmacol Exp Ther. 1993 Dec;267(3):1386-94.

PMID:
8263800
29.

Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase.

Kimes AS, Vaupel DB, London ED.

Psychopharmacology (Berl). 1993;112(4):521-4.

PMID:
7532866
30.
32.
33.

Tripelennamine interactions with the psychotomimetic sigma agonist N-allylnormetazocine.

Vaupel DB.

Pharmacol Biochem Behav. 1989 Jul;33(3):717-20.

PMID:
2555824
34.
35.

Flupirtine antinociception in the dog is primarily mediated by nonopioid supraspinal mechanisms.

Vaupel DB, Nickel B, Becketts K.

Eur J Pharmacol. 1989 Mar 29;162(3):447-56.

PMID:
2744078
36.

Guinea-pig vas deferens preparation may contain both receptors and phencyclidine receptors.

Vaupel DB, Su TP.

Eur J Pharmacol. 1987 Jul 2;139(1):125-8.

PMID:
2888662
37.

Pharmacologic and reinforcing properties of phencyclidine and the enantiomers of N-allylnormetazocine in the dog.

Vaupel DB, Risner ME, Shannon HE.

Drug Alcohol Depend. 1986 Oct;18(2):173-94.

PMID:
3780414
38.

Phencyclidine analogs and precursors: rotarod and lethal dose studies in the mouse.

Vaupel DB, McCoun D, Cone EJ.

J Pharmacol Exp Ther. 1984 Jul;230(1):20-7.

PMID:
6747825
39.

Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog.

Vaupel DB.

Eur J Pharmacol. 1983 Sep 2;92(3-4):269-74.

PMID:
6313397
40.

Progress report from the NIDA Addiction Research Center (preclinical laboratory), Lexington, Kentucky.

Gorodetzky CW, Cone EJ, Goldberg SR, Herling S, Risner ME, Shannon HE, Vaupel DB.

NIDA Res Monogr. 1983 Apr;43:85-91. No abstract available.

PMID:
6135996
41.

Effects of cycloalkyl ring analogs of phencyclidine on behavior in rodents.

Shannon HE, McQuinn RL, Vaupel DB, Cone EJ.

J Pharmacol Exp Ther. 1983 Feb;224(2):327-33.

PMID:
6822958
42.

Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens.

Vaupel DB, Morton EC.

Pharmacol Biochem Behav. 1982 Sep;17(3):539-45.

PMID:
6292959
43.

Monohydroxymetabolites of phencyclidine (PCP): activities and urinary excretion by rat, dog and mouse.

Cone EJ, Vaupel DB, Yousefnejad D.

J Pharm Pharmacol. 1982 Mar;34(3):197-9. No abstract available.

PMID:
6121902
44.

Phencyclidine metabolism: resolution, structure, and biological activity of the isomers of the hydroxy metabolite, 4-phenyl-4-(1-piperidinyl)cyclohexanol.

Carroll FI, Brine GA, Boldt KG, Cone EJ, Yousefnejad D, Vaupel DB, Buchwald WF.

J Med Chem. 1981 Sep;24(9):1047-51.

PMID:
7288819
45.

A pharmacologic comparison between phencyclidine, its precursor, metabolites, and a quaternary derivative in the dog.

Vaupel DB, Cone EJ.

NIDA Res Monogr. 1981 Feb;34:180-6. No abstract available.

PMID:
6783929
46.

Interdisciplinary studies on phencyclidine at the Addiction Research Center, Lexington, Kentucky [proceedings].

Jasinski DR, Shannon HE, Vaupel DB, Cone EJ, Risner ME, McQuinn RL, Su TP, Pickworth WB.

Psychopharmacol Bull. 1980 Oct;16(4):79-81. No abstract available.

PMID:
7454947
47.

Phencyclidine: Detection and measurement of toxic precursors and analogs in lllicit samples.

Cone EJ, Vaupel DB, Buchwald WF.

J Anal Toxicol. 1980 May-Jun;4(3):119-23. No abstract available.

PMID:
7421145
48.

Pharmacology of phenethylamine trace amines in the dog--discussion.

Shannon HE, Vaupel DB, Risner ME, Cone EJ.

Psychopharmacol Bull. 1980 Jan;16(1):54-5. No abstract available.

PMID:
7360843
49.

The inhibition of food intake in the dog by LDS, mescaline, psilocin, d-amphetamine and phenylisopropylamine derivatives.

Vaupel DB, Nozaki M, Martin WR, Bright LD, Morton EC.

Life Sci. 1979 Jun 25;24(26):2427-31. No abstract available.

PMID:
481115
50.

Progress report from the NIDA Addiction Research Center.

Jasinski DR, Cone EJ, Gorodetzky CW, Risner ME, Shannon HE, Su TP, Vaupel DB.

NIDA Res Monogr. 1979;27:61-9. No abstract available.

PMID:
232908

Supplemental Content

Loading ...
Support Center